Microneedle Drug Delivery CRO/CDMO
Hours: 8:30 AM–5:30 PMSales: +86 10 8928 7035Business: bd@casmn.com
CASMN — Beijing CAS Microneedle TechnologyStart a Project
EN / 中文EN
🇨🇳 中文EN English
Menu
Home
SolutionsView all SolutionsDrug Delivery CRO/CDMOMedical Device CDMOSkincare ODM/OEMMicroneedle Essence OilMicroneedle Mold Customization
CapabilitiesView all CapabilitiesFeasibility AssessmentFormulation DevelopmentProcess DevelopmentAnalytical EvaluationPilot Scale-UpClinical-Stage SupportCommercial Manufacturing
TechnologiesView all TechnologiesDissolving MicroneedlesCoated MicroneedlesSwelling Microneedles
Manufacturing
AboutView all AboutCompanyQualifications & HonorsResearch & Intellectual PropertyMilestonesNews & Insights
ContactStart a Project

FROM R&D TO SCALE MANUFACTURING

Microneedle Development and Manufacturing Platform

CASMN connects R&D, pilot-scale development and manufacturing capabilities across its Beijing and Chongqing facilities to support project-specific process development, scale-up, technology transfer and manufacturing.
Discuss a Manufacturing ProjectView Facilities

01 · MANUFACTURING CAPABILITY OVERVIEW

Coordinated R&D, Pilot Scale-Up and Scale Manufacturing

The Beijing integrated R&D base supports project research, process development and pilot-scale transition. The Chongqing Changshou manufacturing base supports project-specific scale manufacturing. Capacity figures below apply to the stated facility or production line and are not universal claims for every microneedle product.
Approx. 4,000 m²Beijing Integrated R&D Base
Approx. 8,000 m²Chongqing Changshou Manufacturing Base
>100 million patches/yearChongqing skincare and daily-care manufacturing line

02 · TWO-SITE COLLABORATION

Beijing R&D and Pilot Scale-Up Connected with Chongqing Manufacturing

Controlled operating environment of the Beijing integrated R&D and pilot base

Beijing Integrated R&D Base

Research, Process Development and Pilot Scale-Up

The approximately 4,000 m² base supports application research and technical services for microneedle and transdermal technologies across drug products, medical devices and daily-care products. It provides CRO/CDMO project-development capabilities and pilot-scale capacity of 10 million patches per year.

  • Application research and technical services
  • CRO/CDMO project development
  • Formulation and process development
  • Process scale-up and pilot preparation
  • 10 million patches/year pilot-scale capacity
Controlled production area at the Chongqing Changshou manufacturing base

Chongqing Changshou Manufacturing Base

Scale Manufacturing and Commercial-Production Transition

The approximately 8,000 m² base was built to Grade C cleanroom standards and holds Class II medical-device manufacturing qualification. It supports scale manufacturing for dissolving microneedles and microcrystal patches. The daily-care product line has annual capacity exceeding 100 million patches, supported by relevant quality, environmental and occupational health and safety management systems.

  • Scale manufacturing
  • Grade C cleanroom environment
  • Class II medical-device manufacturing qualification
  • Daily-care line capacity above 100 million patches/year
  • Transition support from customized development to commercial production

03 · SCALE MANUFACTURING LINES

Manufacturing Capacity for Different Product Pathways

A

Dissolving Microneedle Transdermal Patch Scale Manufacturing Line

The line is located in a Class 10,000 clean manufacturing area and is designed to support scale production of dissolving microneedles and microcrystal patches.

Environment
Class 10,000 clean manufacturing area
Designed capacity
More than 100 million patches/year
Microneedle solution preparation, forming, drying, cleaning and packaging equipment
B

Class II Medical-Device Swelling Microneedle Patch Scale Manufacturing Line

The line is located in a Class 100,000 clean production area and has a designed annual capacity of 10 million patches to support scale manufacturing of swelling-microneedle medical-device products.

Environment
Class 100,000 clean production area
Designed capacity
10 million patches/year

05 · QUALITY MANAGEMENT

Quality Management Across Environment, Process and Systems

Controlled production area at the Chongqing Changshou manufacturing base
01

Controlled Manufacturing Environment

Controlled production areas are configured according to product and process requirements, with management of the manufacturing environment and critical operations.

Quality-control laboratory at the Chongqing Changshou manufacturing base
02

Quality Testing and Process Traceability

Quality-control facilities, process records and relevant testing activities support monitoring of raw materials, manufacturing processes and finished-product quality.

03

Management Systems

The following details are synchronized with the current Qualifications & Honors page. Continued validity remains subject to the applicable surveillance audits.

  • ISO 9001:2015Valid through 4 March 2028, subject to surveillance audits
  • ISO 13485:2016 / EN ISO 13485:2016Valid from 21 January 2025 to 20 January 2028, subject to satisfactory surveillance audits.
  • ISO 22716:2007Valid through 13 February 2028, subject to surveillance audits
  • ISO 45001:2018Valid through 4 March 2028, subject to surveillance audits
  • US FDA Cosmetic GMP Guidelines (2008)Valid through 13 February 2028, subject to surveillance audits
View Qualifications & Honors →

CORE MANUFACTURING PROCESS

RT-SMP® Room-Temperature Printing Process

Company materials identify RT-SMP® as a core manufacturing process. Microneedle parameters and patch shapes can be adjusted according to project requirements, supporting process development and manufacturing translation across different product pathways. This public page does not extend that description into unverified universal performance or efficiency claims.

Technical Review — Reviewed by: CASMN R&D Team · Last reviewed: August 2026

06 · PROJECT ENGAGEMENT

Advance Your Microneedle Project into Pilot Scale-Up and Manufacturing

Share the product pathway, payload, development stage, target market and expected scale. The team will conduct an initial assessment using the coordinated capabilities of the Beijing R&D and pilot base and the Chongqing manufacturing base.Discuss a Manufacturing Project →